

PRESS RELEASE

INSTITUT BERGONIE ANNOUNCES THE PRESENTATION OF TRIAL IN PROGRESS POSTER ON THE CAIRE STUDY AT THE 2022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

CAIRE, first proof-of-concept study investigating tazemetostat combined with immunotherapy (durvalumab) in patients with solid tumors

Bordeaux, June 3, 2022 - Institut BERGONIE, a tertiary cancer center, focused on the development of novel cancer immunotherapies and predictive biomarkers, today will present a trial in progress poster, on the basket CAIRE clinical trial, at the American Society of Clinical Oncology (ASCO) Annual Meeting. CAIRE, a proof-of-concept (POC) trial, is evaluating tazemetostat, an oral EZH2 inhibitor (Epizyme), in combination with durvalumab, an anti-PD-L1 inhibitor, (AstraZeneca) in patients with a variety of advanced solid tumors.

“Our CAIRE trial is rapidly progressing through four independent cohorts including: pancreatic cancer, MSS colorectal cancer, soft-tissue sarcomas and tumors with presence of tertiary lymphoid structures” said Pr Antoine ITALIANO , M.D., PhD, head of the early phase trials Unit at Institut Bergonié. “Furthermore, we are also pleased to see TLS positivity rates tracking with expectations in our biomarker-driven cohort and we remain on-track to report data next year.”

Poster Presentation Details:

Poster Title: CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.

Presenter: Antoine Italiano, MD, PhD Institut Bergonié, Bordeaux, France

Session Title: Developmental Therapeutics – Immunotherapy

Abstract Number: TPS2703

Date and Time: Sunday, June 5, 2022; 9:00am

Highlights from the trial in progress poster include the selection criteria for the ongoing CAIRE study trial and an outline the future biomarker plan:

Epizyme, Inc. is providing tazemetostat and AstraZeneca is providing durvalumab for the CAIRE study.

ABOUT INSTITUT BERGONIE:

The Institut Bergonié is the Comprehensive Cancer Center of the Nouvelle-Aquitaine region. We offer dedicated inpatient and outpatient cancer treatment including radiotherapy and chemotherapy as well as a number of related support services. As a non-profit private hospital dedicated to public service, we have a three-fold mission: patient care, research and oncology education. We are a part of UNICANCER, a national hospital network of 20 French Comprehensive Cancer Centers (FCCC) which are entirely devoted to fighting cancer with the same unique model for patient care. Together with our partner Bordeaux University Hospital Centre (CHU), we are the regional reference center for oncology in Nouvelle-Aquitaine.

For more information, visit www.bergonie.fr and follow @BERGONIE33 on Twitter.

Press contact: Carmona G erald - g.carmona@bordeaux.unicancer.fr